Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Posternak, M. A. Articles by Miller, I. W. Search for Related Content PubMed Citation Articles by Posternak, M. A. Articles by Miller, I. W. Depression Antidepressants Other Research Techniques

A Reevaluation of the Exclusion Criteria Used in Antidepressant Efficacy Trials

OBJECTIVE: Antidepressant efficacy trials use multiple exclusion criteria that are intended primarily to maximize differences between the drug and placebo. These exclusion criteria were implemented prior to having undergone rigorous testing, however, and it is unclear whether they accomplish their intended goal. The authors review the current state of knowledge about treatment response rates in individuals who are typically excluded from antidepressant efficacy trials. METHOD: After reviewing 31 antidepressant efficacy trials published between 1994 and 1998, the authors identified 10 commonly used exclusion criteria. A computerized MEDLINE search and a manual search were used to identify studies evaluating the efficacy of antidepressant medications in populations of subjects typically excluded from antidepressant efficacy trials. RESULTS: Three exclusion criteria—short episode duration, mild severity of illness, and positive response during the placebo lead-in phase—are used primarily to reduce placebo response rates. Preliminary evidence suggests that, of those three criteria, only a short episode duration has been associated with less robust differences between drug and placebo response rates. The seven other exclusion criteria, including various psychiatric comorbidities, long duration of illness, medical comorbidity, and prior nonresponse to treatment, are used because individuals who meet those criteria are believed to have lower response rates to somatic therapy. Although such individuals are often found to have lower response rates to somatic therapy, they also appear to have lower response rates to placebo, and there is little evidence to suggest that drug-placebo differences are any less robust in these individuals. CONCLUSIONS: Many of the standard exclusion criteria currently used in antidepressant efficacy trials may not be achieving their intended goal of maximizing drug-placebo differences. The practice of excluding subjects with particular clinical profiles, which greatly reduces the generalizability of antidepressant efficacy trials, appears to lack empirical support.

This article has been cited by other articles:

				M. A. POSTERNAK and M. ZIMMERMAN Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: Meta-analysis The British Journal of Psychiatry, April 1, 2007; 190(4): 287 - 292. [Abstract] [Full Text] [PDF]

				B. N. Gaynes, A. J. Rush, M. H. Trivedi, S. R. Wisniewski, G. K. Balasubramani, D. C. Spencer, T. Petersen, M. Klinkman, D. Warden, L. Nicholas, et al. Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis Ann. Fam. Med, March 1, 2007; 5(2): 126 - 134. [Abstract] [Full Text] [PDF]

				A. H. Glassman, J. T. Bigger, M. Gaffney, P. A. Shapiro, and J. R. Swenson Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry, March 1, 2006; 63(3): 283 - 288. [Abstract] [Full Text] [PDF]

				M. H. Trivedi, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R. H. Howland, B. Lebowitz, P. J. McGrath, et al. Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice Am J Psychiatry, January 1, 2006; 163(1): 28 - 40. [Abstract] [Full Text] [PDF]

				R. H. Dworkin, J. Katz, and M. J. Gitlin Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain Neurology, December 29, 2005; 65(12_suppl_4): S7 - S19. [Abstract] [Full Text] [PDF]

				M. Zimmerman, I. Chelminski, and M. A. Posternak Generalizability of Antidepressant Efficacy Trials: Differences Between Depressed Psychiatric Outpatients Who Would or Would Not Qualify for an Efficacy Trial Am J Psychiatry, July 1, 2005; 162(7): 1370 - 1372. [Abstract] [Full Text] [PDF]

				M. Zimmerman, M. Posternak, M. Friedman, N. Attiullah, S. Baymiller, R. Boland, S. Berlowitz, S. Rahman, K. Uy, and S. Singer Which Factors Influence Psychiatrists' Selection of Antidepressants? Am J Psychiatry, July 1, 2004; 161(7): 1285 - 1289. [Abstract] [Full Text] [PDF]

				A. H. Glassman, C. M. O'Connor, R. M. Califf, K. Swedberg, P. Schwartz, J. T. Bigger Jr, K. R. R. Krishnan, L. T. van Zyl, J. R. Swenson, M. S. Finkel, et al. Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina JAMA, August 14, 2002; 288(6): 701 - 709. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us